Novel formulations for topical delivery of tranexamic acid: assessing the need of epidermal targeting for hyperpigmentation disorders
- PMID: 37086183
- DOI: 10.1080/17425247.2023.2206645
Novel formulations for topical delivery of tranexamic acid: assessing the need of epidermal targeting for hyperpigmentation disorders
Abstract
Introduction: Tranexamic acid is used for the treatment of hyperpigmentation, and the topical route is the most favorable route for its administration. Tranexamic acid lowers plasmin and tyrosinase, which reduces melanin and skin hyperpigmentation. Low penetration through the outer layer of skin and low availability at target melanocyte cells limit tranexamic acid topical administration. Different novel delivery systems like liposomes, microneedles, topical beads, and microparticles can help in overcoming these limitations.
Areas covered: The mechanism of action of tranexamic acid and novel delivery systems for its topical delivery have been discussed. Further, patents related to the topical delivery of tranexamic acid and clinical trials undertaken to analyze their potential have been discussed.
Expert opinion: Targeting tranexamic acid in the epidermal layer makes more amount of drug available for action on melanocytes, the target site for tranexamic acid. Novel drug delivery formulations like liposomes, solid lipid nanoparticles, nano-lipidic carriers, and topical beads have the potential of achieving epidermal targeting. Epidermal targeting of tranexamic acid can help in the superior delivery of the drug, making its topical treatment more efficient.
Keywords: Epidermal targeting; hyperpigmentation disorders; melasma; nano drug delivery systems; topical drug delivery; tranexamic acid.
Similar articles
-
Targeting delivery and minimizing epidermal diffusion of tranexamic acid by hyaluronic acid-coated liposome nanogels for topical hyperpigmentation treatment.Drug Deliv. 2021 Dec;28(1):2100-2107. doi: 10.1080/10717544.2021.1983081. Drug Deliv. 2021. PMID: 34596008 Free PMC article.
-
Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation.J Drugs Dermatol. 2019 May 1;18(5):454-459. J Drugs Dermatol. 2019. PMID: 31141852 Clinical Trial.
-
In vitro human skin concentrations following topical application of 2% tranexamic acid in co-enhancer cream and branded cream formulations.J Cosmet Dermatol. 2020 Oct;19(10):2656-2662. doi: 10.1111/jocd.13301. Epub 2020 Jan 21. J Cosmet Dermatol. 2020. PMID: 31961048
-
Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: A review.J Cosmet Dermatol. 2023 Apr;22(4):1157-1162. doi: 10.1111/jocd.15561. Epub 2022 Dec 27. J Cosmet Dermatol. 2023. PMID: 36575866 Review.
-
Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies.Dermatol Ther. 2017 May;30(3). doi: 10.1111/dth.12465. Epub 2017 Jan 30. Dermatol Ther. 2017. PMID: 28133910 Review.
Cited by
-
Evaluation of the In Vivo Skin Penetration of TXVector by Confocal Raman Spectroscopy.J Cosmet Dermatol. 2025 Feb;24(2):e16696. doi: 10.1111/jocd.16696. Epub 2024 Nov 27. J Cosmet Dermatol. 2025. PMID: 39600220 Free PMC article.
-
Clinical Safety and Efficacy of Hyaluronic Acid-Niacinamide-Tranexamic Acid Injectable Hydrogel for Multifactorial Facial Skin Quality Enhancement with Dark Skin Lightening.Gels. 2025 Jun 26;11(7):495. doi: 10.3390/gels11070495. Gels. 2025. PMID: 40710660 Free PMC article.
-
Enhancing skin delivery of tranexamic acid via esterification: synthesis and evaluation of alkyl ester derivatives.RSC Adv. 2024 Nov 5;14(47):34996-35004. doi: 10.1039/d4ra06266c. eCollection 2024 Oct 29. RSC Adv. 2024. PMID: 39502868 Free PMC article.
-
QbD-based co-loading of paclitaxel and imatinib mesylate by protamine-coated PLGA nanoparticles effective on breast cancer cells.Nanomedicine (Lond). 2024;19(26):2211-2227. doi: 10.1080/17435889.2024.2353557. Epub 2024 Jun 27. Nanomedicine (Lond). 2024. PMID: 38934510 Free PMC article.
-
Central composite design augmented quality-by-design-based systematic formulation of erlotinib hydrochloride-loaded chitosan-poly (lactic-co-glycolic acid) nanoparticles.Ther Deliv. 2024;15(6):427-447. doi: 10.1080/20415990.2024.2342771. Epub 2024 May 9. Ther Deliv. 2024. PMID: 38722230 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources